Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2024

Open Access 01-12-2024 | Six Minute Walk Test | Research

Validation of a modified version of the gross motor function measure in PPPR5D related neurodevelopmental disorder

Authors: Cara H. Kanner, David Uher, Kyle Zreibe, Gabriella Beard, Madison Patterson, Matthew Harris, Jerome Doerger, Sean Calamia, Wendy K. Chung, Jacqueline Montes

Published in: Orphanet Journal of Rare Diseases | Issue 1/2024

Login to get access

Abstract

Background

Protein phosphatase 2 regulatory subunit B’ Delta (PPP2R5D)-related neurodevelopmental disorder is a rare genetic condition caused by pathogenic variants in the PPP2R5D gene. Clinical signs include hypotonia, gross motor delay, intellectual disability (ID), epilepsy, speech delays, and abnormal gait among other impairments. As this disorder was recognized within the last decade, there are only 103 people published diagnoses to date. A thorough understanding of the motor manifestations of this disorder has not yet been established. Knowledge of the natural history of PPP2R5D related neurodevelopmental disorder will lead to improved standard of care treatments as well as serve as a baseline foundation for future clinical trials. Appropriate outcome measures are necessary for use in clinical trials to uniformly measure function and monitor potential for change. The aim of this study was to validate the gross motor function measure (GMFM) in children and adults with PPP2R5D-related neurodevelopmental disorder in order to better characterize the disorder.

Results

Thirty-eight individuals with PPP2R5D pathogenic variants, median age 8.0 years (range 1–27) were evaluated. Gross motor, upper limb and ambulatory function were assessed using the GMFM-66, six-minute walk test (6MWT), 10-meter walk run (10MWR), timed up and go (TUG), and revised upper limb module (RULM). The pediatric disability inventory computer adapted test (PEDI-CAT) captured caregiver reported assessment. Median GMFM-66 score was 60.6 (SD = 17.3, range 21.1–96.0). There were strong associations between the GMFM-66 and related mobility measures, 10MWR (rs = −0.733; p < 0.001), TUG (rs= −0.747; p = 0.003), 6MWT (r = 0.633; p = 0.006), RULM (r = 0.763; p < 0.001), PEDICAT-mobility (r = 0.855; p < 0.001), and daily activities (r = 0.822; p < 0.001) domains.

Conclusions

The GMFM is a valid measure for characterizing motor function in individuals with PPP2R5D related neurodevelopmental disorder. The GMFM-66 had strong associations with the RULM and timed function tests which characterized gross motor, upper limb and ambulatory function demonstrating concurrent validity. The GMFM-66 was also able to differentiate between functional levels in PPP2R5D related neurodevelopmental disorder demonstrating discriminant validity. Future studies should examine its sensitivity to change over time, ability to identify sub-phenotypes, and suitability as an outcome measure in future clinical trials in individuals with PPP2R5D variants.
Appendix
Available only for authorised users
Literature
1.
Madaan P, Kaur A, Saini L, Paria P, Vyas S, Sharma AR, et al. PPP2R5D-Related Neurodevelopmental Disorder or Developmental and Epileptic Encephalopathy?: A Novel Phenotypic Description and Review of Published Cases. Neuropediatrics. 2022;53(1):20–5.CrossRefPubMed
2.
Biswas D, Cary W, Nolta JA. PPP2R5D-Related Intellectual Disability and Neurodevelopmental Delay: A Review of the Current Understanding of the Genetics and Biochemical Basis of the Disorder. Int J Mol Sci. 2020;21(4).
3.
Houge G, Haesen D, Vissers LE, Mehta S, Parker MJ, Wright M, et al. B56δ-related protein phosphatase 2A dysfunction identified in patients with intellectual disability. J Clin Invest. 2015;125(8):3051–62.CrossRefPubMedPubMedCentral
4.
Yan L, Shen R, Cao Z, Han C, Zhang Y, Liu Y, et al. A Novel Missense Variant in the Gene PPP2R5D Causes a Rare Neurodevelopmental Disorder with Increased Phenotype. Biomed Res Int. 2021;2021:6661860.CrossRefPubMedPubMedCentral
5.
6.
Shang L, Henderson LB, Cho MT, Petrey DS, Fong CT, Haude KM, et al. De novo missense variants in PPP2R5D are associated with intellectual disability, macrocephaly, hypotonia, and autism. Neurogenetics. 2016;17(1):43–9.CrossRefPubMed
7.
Simons Searchlight. Simons Searchlight Registry Update PPP2R5D. Internet March 2021.
8.
Kim CY, Wirth T, Hubsch C, Nemeth AH, Okur V, Anheim M, et al. Early-Onset Parkinsonism Is a Manifestation of the PPP2R5D p.E200K Mutation. Ann Neurol. 2020;88(5):1028-33.
9.
Krosschell KJ, Young SD, Peterson I, Curry M, Mazzella A, Jarecki J, et al. Clinical and Research Readiness for Spinal Muscular Atrophy: The Time Is Now for Knowledge Translation. Phys Ther. 2022.
10.
Russell DJ, Rosenbaum PL, Cadman DT, Gowland C, Hardy S, Jarvis S. The gross motor function measure: a means to evaluate the effects of physical therapy. Dev Med Child Neurol. 1989;31(3):341–52.CrossRefPubMed
11.
Russell D, Palisano R, Walter S, Rosenbaum P, Gemus M, Gowland C, et al. Evaluating motor function in children with Down syndrome: validity of the GMFM. Dev Med Child Neurol. 1998;40(10):693–701.CrossRefPubMed
12.
Nelson L, Owens H, Hynan LS, Iannaccone ST. The gross motor function measure is a valid and sensitive outcome measure for spinal muscular atrophy. Neuromuscul Disord. 2006;16(6):374–80.CrossRefPubMed
13.
Salazar R, Beenders S, LaMarca NM, Thornburg O, Rubin-Thompson L, Snow A, et al. Cross-sectional, quantitative analysis of motor function in females with HNRNPH2-related disorder. Res Dev Disabil. 2021;119: 104110.CrossRefPubMed
14.
Sato T, Adachi M, Nakamura K, Zushi M, Goto K, Murakami T, et al. The gross motor function measure is valid for Fukuyama congenital muscular dystrophy. Neuromuscul Disord. 2017;27(1):45–9.CrossRefPubMed
15.
Russell DJ, Avery LM, Rosenbaum PL, Raina PS, Walter SD, Palisano RJ. Improved scaling of the gross motor function measure for children with cerebral palsy: evidence of reliability and validity. Phys Ther. 2000;80(9):873–85.CrossRefPubMed
16.
Avery LM, Russell DJ, Raina PS, Walter SD, Rosenbaum PL. Rasch analysis of the Gross Motor Function Measure: validating the assumptions of the Rasch model to create an interval-level measure. Arch Phys Med Rehabil. 2003;84(5):697–705.CrossRefPubMed
17.
Brunton LK, Bartlett DJ. Validity and reliability of two abbreviated versions of the Gross Motor Function Measure. Phys Ther. 2011;91(4):577–88.CrossRefPubMed
18.
Russell DJ, Avery LM, Walter SD, Hanna SE, Bartlett DJ, Rosenbaum PL, et al. Development and validation of item sets to improve efficiency of administration of the 66-item Gross Motor Function Measure in children with cerebral palsy. Dev Med Child Neurol. 2010;52(2):e48-54.CrossRefPubMed
19.
Rosenbaum PL, Palisano RJ, Bartlett DJ, Galuppi BE, Russell DJ. Development of the Gross Motor Function Classification System for cerebral palsy. Dev Med Child Neurol. 2008;50(4):249–53.CrossRefPubMed
20.
Paulson A, Vargus-Adams J. Overview of Four Functional Classification Systems Commonly Used in Cerebral Palsy. Children (Basel). 2017;4(4).
21.
Mazzone ES, Mayhew A, Montes J, Ramsey D, Fanelli L, Young SD, et al. Revised upper limb module for spinal muscular atrophy: Development of a new module. Muscle Nerve. 2017;55(6):869–74.CrossRefPubMed
22.
Haley SM, Coster WJ, Dumas HM, Fragala-Pinkham MA, Kramer J, Ni P, et al. Accuracy and precision of the Pediatric Evaluation of Disability Inventory computer-adaptive tests (PEDI-CAT). Dev Med Child Neurol. 2011;53(12):1100–6.CrossRefPubMedPubMedCentral
23.
Dumas HM, Fragala-Pinkham MA, Rosen EL, O’Brien JE. Construct validity of the pediatric evaluation of disability inventory computer adaptive test (PEDI-CAT) in children with medical complexity. Disabil Rehabil. 2017;39(23):2446–51.CrossRefPubMed
24.
Dunaway Young S, Montes J, Kramer SS, Marra J, Salazar R, Cruz R, et al. Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve. 2016;54(5):836–42.CrossRefPubMed
25.
Li AM, Yin J, Au JT, So HK, Tsang T, Wong E, et al. Standard reference for the six-minute-walk test in healthy children aged 7 to 16 years. Am J Respir Crit Care Med. 2007;176(2):174–80.CrossRefPubMed
26.
McKay MJ, Baldwin JN, Ferreira P, Simic M, Vanicek N, Burns J. Reference values for developing responsive functional outcome measures across the lifespan. Neurology. 2017;88(16):1512–9.CrossRefPubMed
27.
Bartels B, de Groot JF, Terwee CB. The six-minute walk test in chronic pediatric conditions: a systematic review of measurement properties. Phys Ther. 2013;93(4):529–41.CrossRefPubMed
28.
McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10101):1489–98.CrossRefPubMed
29.
Claeys KG, D'Hondt A, Fache L, Peers K, Depuydt CE. Six-Minute Walk Distance Is a Useful Outcome Measure to Detect Motor Decline in Treated Late-Onset Pompe Disease Patients. Cells. 2022;11(3).
30.
Verbecque E, Schepens K, Theré J, Schepens B, Klingels K, Hallemans A. The Timed Up and Go Test in Children: Does Protocol Choice Matter? A Systematic Review Pediatr Phys Ther. 2019;31(1):22–31.CrossRefPubMed
31.
Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142–8.CrossRefPubMed
32.
Williams EN, Carroll SG, Reddihough DS, Phillips BA, Galea MP. Investigation of the timed “up & go” test in children. Dev Med Child Neurol. 2005;47(8):518–24.CrossRefPubMed
33.
Krosschell KJ, Townsend EL, Kiefer M, Simeone SD, Zumpf K, Welty L, et al. Natural history of 10-meter walk/run test performance in spinal muscular atrophy: A longitudinal analysis. Neuromuscul Disord. 2022;32(2):125–34.CrossRefPubMed
34.
Mirzaa G, Foss K, Nattakom M, Chung WK. PPP2R5D-Related Neurodevelopmental Disorder. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, et al., editors. GeneReviews((R)). Seattle (WA)1993.
35.
Walton MK, Powers JH 3rd, Hobart J, Patrick D, Marquis P, Vamvakas S, et al. Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force. Value Health. 2015;18(6):741–52.CrossRefPubMedPubMedCentral
Metadata
Title
Validation of a modified version of the gross motor function measure in PPPR5D related neurodevelopmental disorder
Authors
Cara H. Kanner
David Uher
Kyle Zreibe
Gabriella Beard
Madison Patterson
Matthew Harris
Jerome Doerger
Sean Calamia
Wendy K. Chung
Jacqueline Montes
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2024
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-024-03067-3

Other articles of this Issue 1/2024

Orphanet Journal of Rare Diseases 1/2024 Go to the issue

Research

The value of knowing: preferences for genetic testing to diagnose rare muscle diseases

Research

Epidemiology of autoimmune liver disease in Korea: evidence from a nationwide real-world database

Research

Cerebrotendinous Xanthomatosis patients with late diagnosed in single orthopedic clinic: two novel variants in the CYP27A1 gene

Research

Exploring the support needs of Australian parents of young children with Usher syndrome: a qualitative thematic analysis

Research

Coexistence of meningioma and craniofacial fibrous dysplasia: a case series of clinicopathological study and literature review

Research

Dual rare genetic diseases in five pediatric patients: insights from next-generation diagnostic methods